Biodesix (BDSX) Aktienübersicht
Biodesix, Inc. ist ein Unternehmen für diagnostische Lösungen. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 4/6 |
| Künftiges Wachstum | 1/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 2/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
BDSX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Biodesix, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$21.42 |
| 52-Wochen-Hoch | US$24.92 |
| 52-Wochen-Tief | US$5.26 |
| Beta | 0.52 |
| 1 Monat Veränderung | 42.70% |
| 3 Monate Veränderung | 63.14% |
| 1 Jahr Veränderung | 247.05% |
| 3 Jahre Veränderung | -3.51% |
| 5 Jahre Veränderung | -90.61% |
| Veränderung seit IPO | -91.64% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jul 09
BDSX: Durable Revenue Outlook And EBITDA Breakeven Progress Will Drive Upside
Biodesix's analyst fair value estimate has risen from $22.00 to $26.00 as analysts highlight expectations for durable revenue growth, solid gross margins, and a path toward adjusted EBITDA breakeven that could support a higher future P/E multiple. Analyst Commentary Recent Street research on Biodesix has pointed to a mix of optimism about the business model and a clear focus on execution milestones.
Narrativ-Update • Jun 25
BDSX: Durable Gross Margins And EBITDA Breakeven Path Will Support Higher Confidence
The analyst price target for Biodesix has been revised modestly higher from about $30.50 to roughly $30.83, with analysts pointing to expectations for durable top line growth, strong gross margins, and a path toward adjusted EBITDA breakeven as key supports for the updated view. Analyst Commentary Recent research on Biodesix highlights a generally constructive stance, with price targets clustered in the high $20s to low $30s and commentary focused on growth, margins, and the path to adjusted EBITDA breakeven.Narrativ-Update • Jun 11
BDSX: Larger Lung Nodule Study And 2026 Guidance Will Support Upside
Analysts have raised their price target on Biodesix by $2 to $22, citing updated expectations around fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Biodesix raised its consolidated earnings guidance for fiscal 2026, now expecting total revenue of US$108–114 million versus prior guidance of US$106–112 million, with the midpoint implying approximately 25% growth over 2025 compared with the earlier midpoint of 23% growth.Narrativ-Update • May 28
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Higher Confidence
Analysts nudged their Biodesix price target higher by $0.50 to $30.50, citing Street research that highlights slightly adjusted growth and discount rate assumptions, better profit margin expectations, and recent upgrades tied to revenue guidance and an improved balance sheet. Analyst Commentary Recent Street research gives you a mixed but constructive picture of how analysts are thinking about Biodesix, with some focusing on execution and balance sheet progress, and others more cautious around what is already reflected in the valuation.Recent updates
Narrativ-Update • Jul 09
BDSX: Durable Revenue Outlook And EBITDA Breakeven Progress Will Drive Upside
Biodesix's analyst fair value estimate has risen from $22.00 to $26.00 as analysts highlight expectations for durable revenue growth, solid gross margins, and a path toward adjusted EBITDA breakeven that could support a higher future P/E multiple. Analyst Commentary Recent Street research on Biodesix has pointed to a mix of optimism about the business model and a clear focus on execution milestones.Narrativ-Update • Jun 25
BDSX: Durable Gross Margins And EBITDA Breakeven Path Will Support Higher Confidence
The analyst price target for Biodesix has been revised modestly higher from about $30.50 to roughly $30.83, with analysts pointing to expectations for durable top line growth, strong gross margins, and a path toward adjusted EBITDA breakeven as key supports for the updated view. Analyst Commentary Recent research on Biodesix highlights a generally constructive stance, with price targets clustered in the high $20s to low $30s and commentary focused on growth, margins, and the path to adjusted EBITDA breakeven.Narrativ-Update • Jun 11
BDSX: Larger Lung Nodule Study And 2026 Guidance Will Support Upside
Analysts have raised their price target on Biodesix by $2 to $22, citing updated expectations around fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Biodesix raised its consolidated earnings guidance for fiscal 2026, now expecting total revenue of US$108–114 million versus prior guidance of US$106–112 million, with the midpoint implying approximately 25% growth over 2025 compared with the earlier midpoint of 23% growth.Narrativ-Update • May 28
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Higher Confidence
Analysts nudged their Biodesix price target higher by $0.50 to $30.50, citing Street research that highlights slightly adjusted growth and discount rate assumptions, better profit margin expectations, and recent upgrades tied to revenue guidance and an improved balance sheet. Analyst Commentary Recent Street research gives you a mixed but constructive picture of how analysts are thinking about Biodesix, with some focusing on execution and balance sheet progress, and others more cautious around what is already reflected in the valuation.
Narrativ-Update • May 02
BDSX: Improved Balance Sheet And 2026 Revenue Outlook Will Support Upside
Analysts have lifted their price target on Biodesix to $73.88 from $57.08, citing above-expectation 2026 revenue guidance, three consecutive quarters of execution above target, and a "significantly improved" balance sheet that together support a higher assumed future P/E multiple. Analyst Commentary Recent research commentary points to a more constructive view on Biodesix, with bullish analysts highlighting the company’s 2026 revenue guidance, operating execution, and balance sheet as key reasons for a higher valuation framework.Narrativ-Update • Apr 16
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Upgraded Rating
Analysts have nudged their price target on Biodesix higher to $30.00 from $30, citing 2026 revenue guidance that is 3% ahead of expectations, a "significantly improved" balance sheet, and three consecutive quarters of execution above target as reasons for a more constructive view. Analyst Commentary Bullish Takeaways Bullish analysts view the upgrade to an Outperform rating as a signal that recent execution and guidance support a higher valuation framework than before.Narrativ-Update • Apr 01
BDSX: Strong Guidance And Healthier Balance Sheet Will Support 2026 Momentum
Analysts have raised their price target on Biodesix from $30.00 to $56.14, citing 2026 revenue guidance that is 3% above prior expectations and a "significantly improved" balance sheet, with execution running above target for three consecutive quarters. Analyst Commentary Bullish Takeaways Bullish analysts point to the 2026 revenue guidance coming in 3% above prior expectations as support for a higher valuation range, given that it directly feeds into forward revenue estimates and P/S assumptions.Narrativ-Update • Mar 18
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Upside
Analysts have maintained their price target on Biodesix, citing 2026 revenue guidance that is 3% ahead of expectations, a "significantly improved" balance sheet, and what they see as three consecutive quarters of above target execution heading into 2026. Analyst Commentary The latest upgrade frames Biodesix as entering 2026 with momentum, supported by revenue guidance that sits 3% ahead of expectations and an improved balance sheet.Narrativ-Update • Mar 04
BDSX: Improved Balance Sheet And Guidance Will Support Momentum Into 2026
Analysts have reduced their price target on Biodesix from $35 to $30, citing updated fair value assumptions along with views that recent revenue guidance, improving margins, and a lower discount rate better reflect the company’s execution and balance sheet strength. Analyst Commentary Bullish Takeaways Bullish analysts point to the upgrade to an Outperform rating as a sign that recent execution and guidance are more in line with what they view as fair value.Narrativ-Update • Feb 18
BDSX: Raised 2025 Revenue Guidance Will Support Path To Profitability
Analysts have revised their price target on Biodesix to $40.00 from $40, reflecting updated views on discount rate, revenue growth, profit margin, and future P/E assumptions in their models. What's in the News Biodesix raised its revenue guidance for the fiscal year ending December 31, 2025, estimating total revenue of $88.5 million, above the previously increased range of $84 million to $86 million (company guidance).Narrativ-Update • Feb 02
BDSX: Raised 2025 Revenue Guidance Will Support Path To Profitability
Analysts have adjusted their price target on Biodesix to US$40.00 from US$40, citing updated assumptions around discount rates, revenue growth, profit margin, and future P/E that collectively refine, rather than overhaul, their previous view. What's in the News Biodesix issued new earnings guidance for the fourth quarter ended December 31, 2025, estimating total revenue of US$28.8 million for the period (Key Developments).Narrativ-Update • Jan 19
BDSX: Expanded Diagnostics Partnership Will Drive Revenue Upside In 2025
Analysts have increased their price target on Biodesix to reflect updated views on revenue growth potential and a slightly lower discount rate, while also adjusting expected profit margins and future P/E assumptions to align with their latest models. What's in the News Biodesix issued earnings guidance for the fourth quarter of 2025, estimating total revenue of $28.8 million for the period (Corporate guidance).Analyseartikel • Jan 14
Investors Still Aren't Entirely Convinced By Biodesix, Inc.'s (NASDAQ:BDSX) Revenues Despite 26% Price Jump
Despite an already strong run, Biodesix, Inc. ( NASDAQ:BDSX ) shares have been powering on, with a gain of 26% in the...Narrativ-Update • Jan 05
BDSX: Expanded Diagnostics Partnership And ESR1 Assay Rollout Will Drive Upside
Analysts have lifted their price target on Biodesix to US$20.00 from US$1.50, citing adjusted assumptions around revenue growth, profit margin, discount rate, and a lower future P/E multiple as the key drivers of this revised view. What's in the News Biodesix raised its fiscal 2025 revenue guidance and now expects total revenue between US$84 million and US$86 million for the year (Key Developments).Narrativ-Update • Dec 14
BDSX: Reverse Split And ATM Access Will Support Path To Profitability
Analysts have significantly lifted their price target on Biodesix from $2.00 to $40.00, citing updated models following the 20 for 1 reverse split, a reduced share count, and the company’s ability to utilize its at the market facility to support operations through an expected path to cash flow breakeven and profitability. Analyst Commentary Bullish analysts interpret the new price target framework as a constructive signal for Biodesix, emphasizing that the reset reflects mechanical impacts from the 20 for 1 reverse split rather than a fundamental deterioration in the business outlook.Analyseartikel • Nov 29
Biodesix, Inc.'s (NASDAQ:BDSX) Shares Leap 27% Yet They're Still Not Telling The Full Story
Biodesix, Inc. ( NASDAQ:BDSX ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...Analyseartikel • Nov 05
US$32.50: That's What Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Is Worth After Its Latest Results
Biodesix, Inc. ( NASDAQ:BDSX ) just released its latest quarterly results and things are looking bullish. Revenues and...Analyseartikel • Sep 18
It's Down 27% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
The Biodesix, Inc. ( NASDAQ:BDSX ) share price has softened a substantial 27% over the previous 30 days, handing back...Narrativ-Update • Sep 16
Digital Integration And Expanded Lung Diagnostics Will Broaden Markets
The substantial increase in Biodesix’s consensus price target is accompanied by a modest improvement in forward earnings valuation and a slight rise in discount rate, indicating more favorable future expectations despite a marginally higher cost of capital, with fair value rising markedly to $35.00. What's in the News Biodesix announced a 1-for-20 stock split.Analyseartikel • Jul 29
The Market Lifts Biodesix, Inc. (NASDAQ:BDSX) Shares 67% But It Can Do More
Those holding Biodesix, Inc. ( NASDAQ:BDSX ) shares would be relieved that the share price has rebounded 67% in the...Analyseartikel • Jun 14
Biodesix, Inc. (NASDAQ:BDSX) Stock Rockets 30% But Many Are Still Ignoring The Company
Those holding Biodesix, Inc. ( NASDAQ:BDSX ) shares would be relieved that the share price has rebounded 30% in the...Analyseartikel • May 15
Analysts Just Slashed Their Biodesix, Inc. (NASDAQ:BDSX) EPS Numbers
The latest analyst coverage could presage a bad day for Biodesix, Inc. ( NASDAQ:BDSX ), with the analysts making...Analyseartikel • May 14
It's Unlikely That Biodesix, Inc.'s (NASDAQ:BDSX) CEO Will See A Huge Pay Rise This Year
Key Insights Biodesix's Annual General Meeting to take place on 20th of May Salary of US$588.9k is part of CEO Scott...Analyseartikel • Apr 19
Investors Give Biodesix, Inc. (NASDAQ:BDSX) Shares A 33% Hiding
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 33% in the last...
Neues Narrativ • Apr 03
Sales Force Expansion And CLARIFY Study Will Boost Test Adoption
Expansion of sales force and test adoption, along with CLARIFY study results, are expected to drive revenue growth and improve margins.Analyseartikel • Mar 05
It's Down 30% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 30% in the last...Analyseartikel • Jan 19
The Price Is Right For Biodesix, Inc. (NASDAQ:BDSX) Even After Diving 27%
Biodesix, Inc. ( NASDAQ:BDSX ) shareholders that were waiting for something to happen have been dealt a blow with a 27...Analyseartikel • Nov 21
With A 26% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 26% in the last...Analyseartikel • Sep 24
Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Jun 12
Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear
When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales...Analyseartikel • Mar 03
With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For
The Biodesix, Inc. ( NASDAQ:BDSX ) share price has softened a substantial 25% over the previous 30 days, handing back...Analyseartikel • Jan 04
Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce
Biodesix, Inc. ( NASDAQ:BDSX ) shareholders are no doubt pleased to see that the share price has bounced 28% in the...Analyseartikel • Jul 16
It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 28% in the last...Aktionärsrenditen
| BDSX | US Healthcare | US Markt | |
|---|---|---|---|
| 7D | -2.6% | 0.3% | 0.6% |
| 1Y | 247.1% | 31.7% | 19.5% |
Rendite im Vergleich zur Industrie: BDSX übertraf die Branche US Healthcare , die im vergangenen Jahr eine Rendite von 31.7 erzielte.
Rendite vs. Markt: BDSX übertraf den Markt US, der im vergangenen Jahr eine Rendite von 19.5 erzielte.
Preisvolatilität
| BDSX volatility | |
|---|---|
| BDSX Average Weekly Movement | 15.5% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: Der Aktienkurs von BDSX war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.
Volatilität im Zeitverlauf: BDSXDie wöchentliche Volatilität (16%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2005 | 334 | Scott Hutton | www.biodesix.com |
Biodesix, Inc. ist ein Unternehmen für diagnostische Lösungen. Das Unternehmen bietet blutbasierte Lungentests an, darunter Nodify XL2 und Nodify CDT Tests, die als Nodify Lung Nodule Risk Assessment Tests das Risiko von Lungenkrebs abschätzen und bei der Identifizierung des geeigneten Behandlungspfads helfen und Ärzte bei der Neuklassifizierung des Risikos von Malignität bei Patienten mit verdächtigen Lungenknoten unterstützen. Das Unternehmen bietet auch GeneStrat ddPCR-, GeneStrat NGS- und VeriStrat-Tests als Teil der IQLung-Teststrategie an, die bei der Diagnose von Lungenkrebs eingesetzt werden, um das Vorhandensein von Mutationen im Tumor und den Zustand des Immunsystems des Patienten zu messen und so Behandlungsentscheidungen zu treffen.
Biodesix, Inc.'s Grundlagenzusammenfassung
| BDSX grundlegende Statistiken | |
|---|---|
| Marktanteil | US$229.38m |
| Gewinn(TTM) | -US$31.96m |
| Umsatz(TTM) | US$96.10m |
2.3x
Kurs-Umsatz-Verhältnis-6.9x
Kurs-Gewinn-Verhältnis Ist BDSX zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| BDSX Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$96.10m |
| Kosten der Einnahmen | US$17.62m |
| Bruttogewinn | US$78.48m |
| Sonstige Ausgaben | US$110.43m |
| Gewinn | -US$31.96m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -3.09 |
| Bruttomarge | 81.66% |
| Nettogewinnspanne | -33.26% |
| Schulden/Eigenkapital-Verhältnis | 509.1% |
Wie hat sich BDSX auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/10 22:38 |
| Aktienkurs zum Tagesende | 2026/07/10 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Biodesix, Inc. wird von 10 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Sung Ji Nam | BTIG |
| Kyle Mikson | Canaccord Genuity |
| William Bonello | Craig-Hallum Capital Group LLC |